在适合移植的新诊断多发性骨髓瘤患者中,来那度胺、硼替佐米和地塞米松联合达雷妥尤单抗(GRIFFIN):开放标签、随机、2期试验的最终分析
GRIFFIN研究是一项在美国35个中心开展的开放标签、随机、活性对照2期试验,比较D-RVd与RVd方案在适合移植的新诊断多发性骨髓瘤患者中的疗效。中位随访49.6个月,D-RVd组严格完全缓解率67% vs 48%(OR 2.18),4年无进展生存率87.2% vs 70.0%(HR 0.45)。两组中位总生存均未达到(HR 0.90),安全性事件与既往报告一致,未出现新的安全性信号。
要点
- D-RVd组严格完全缓解率67% vs RVd组48%,OR 2.18(95%CI 1.22-3.89),p=0.0079。
- 4年无进展生存率D-RVd组87.2% vs RVd组70.0%,HR 0.45(95%CI 0.21-0.95),p=0.032。
- 两组中位总生存均未达到,HR 0.90(95%CI 0.31-2.56),p=0.84。
核心结论
- 在适合移植的新诊断多发性骨髓瘤患者中,RVd联合达雷妥尤单抗改善了缓解深度和无进展生存。
- 这些结果支持在3期研究中进行进一步评估。
研究设计与样本
- GRIFFIN为开放标签、随机、活性对照、2期试验,在美国35个研究中心开展。
- 纳入新诊断多发性骨髓瘤患者,年龄18-70岁,ECOG体能状态评分0-2,适合自体造血干细胞移植。
- 患者1:1随机分配至D-RVd组(104例)或RVd组(103例),接受4周期诱导、自体造血干细胞移植、2周期巩固及2年来那度胺±达雷妥尤单抗维持治疗。
主要发现
- 中位随访49.6个月(IQR 47.4-52.1),D-RVd组严格完全缓解率67%(67/100)vs RVd组48%(47/98),OR 2.18(95%CI 1.22-3.89),p=0.0079。
- 4年无进展生存率D-RVd组87.2%(95%CI 77.9-92.8)vs RVd组70.0%(95%CI 55.9-80.3),疾病进展或死亡HR 0.45(95%CI 0.21-0.95),p=0.032。
- 两组中位总生存均未达到,HR 0.90(95%CI 0.31-2.56),p=0.84。
- D-RVd组 vs RVd组最常见的3-4级治疗中出现的不良事件:中性粒细胞减少46%(46/99)vs 23%(23/102),淋巴细胞减少23%(23/99)vs 23%(23/102),白细胞减少17%(17/99)vs 8%(8/102),血小板减少16%(16/99)vs 9%(9/102),肺炎12%(12/99)vs 14%(14/102),低磷血症10%(10/99)vs 11%(11/102)。
- 严重治疗中出现的不良事件D-RVd组46%(46/99)vs RVd组52%(53/102);每组各1例治疗中出现的不良事件导致死亡(D-RVd组为支气管肺炎,RVd组原因不明),均与研究治疗无关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-RVd) in the GRIFFIN study improved the stringent complete response rate by the end of consolidation in transplantation-eligible patients with newly diagnosed multiple myeloma. Here, we report the findings of the predefined final analysis. METHODS: GRIFFIN was an open-label, randomised, active-controlled, phase 2 trial done in 35 research centres in the USA. Patients had newly diagnosed multiple myeloma with measurable disease by M protein or free light chain, were aged 18-70 years, had an ECOG performance score of 0-2, and were eligible for autologous haematopoietic stem-cell transplantation (HSCT). Patients were randomly assigned (1:1) to four D-RVd or RVd induction cycles, autologous HSCT, two D-RVd or RVd consolidation cycles, and lenalidomide with or without daratumumab maintenance therapy for 2 years. Patients received 21-day cycles of oral lenalidomide (25 mg on days 1-14), subcutaneous bortezomib (1·3 mg/m2 on days 1, 4, 8, and 11), oral dexamethasone (40 mg weekly) with or without intravenous daratumumab (16 mg/kg weekly, cycles 1-4; day 1, cycles 5-6). Maintenance therapy (28-day cycles) was oral lenalidomide (10 mg on days 1-21) with or without daratumumab (16 mg/kg intravenously every 4 or 8 weeks, or 1800 mg subcutaneously monthly). Patients could continue lenalidomide maintenance after study treatment completion. The primary endpoint was stringent complete response rate by the end of consolidation in the response-evaluable population, and has already been reported. Here we report updated stringent complete response rates and secondary outcomes including progression-free survival and overall survival. The trial is registered with ClinicalTrials.gov (NCT02874742) and ended on April 8, 2022. FINDINGS: Between Dec 20, 2016, and April 10, 2018, 104 patients were randomly assigned to the D-RVd group and 103 were randomly assigned to the RVd group; most patients were White (85 [82%] in the D-RVd group and 76 [74%] in the RVd group) and male (58 [56%] in the D-RVd group and 60 [58%] in the RVd group). At a median follow-up of 49·6 months (IQR 47·4-52·1), D-RVd improved rates of stringent complete response (67 [67%] of 100] vs 47 [48%] of 98]; odds ratio 2·18 [95% CI 1·22-3·89], p=0·0079), and 4-year progression-free survival was 87·2% (95% CI 77·9-92·8) for D-RVd versus 70·0% (95% CI 55·9-80·3) for RVd, with a hazard ratio (HR) of 0·45 (95% CI 0·21-0·95, p=0·032) for risk of disease progression or death with D-RVd. Median overall survival was not reached for either group (HR 0·90 [95% CI 0·31-2·56], p=0·84). The most common grade 3-4 treatment-emergent adverse events in the D-RVd versus RVd groups were neutropenia (46 [46%] of 99 vs 23 [23%] of 102), lymphopenia (23 [23%] vs 23 [23%]), leukopenia (17 [17%] vs eight [8%]), thrombocytopenia (16 [16%] vs nine [9%]), pneumonia (12 [12%] vs 14 [14%]), and hypophosphataemia (ten [10%] vs 11 [11%]). Serious treatment-emergent adverse events occurred in 46 (46%) of 99 patients in the D-RVd group and in 53 (52%) of 102 patients in the RVd group. One patient in each treatment group reported a treatment-emergent adverse event that resulted in death (bronchopneumonia in the D-RVd group; cause unknown in the RVd group); neither was related to study treatment. No new safety concerns occurred with maintenance therapy. INTERPRETATION: Addition of daratumumab to RVd improved the depth of response and progression-free survival in transplantation-eligible patients with newly diagnosed multiple myeloma. These results justify further evaluation in phase 3 studies. FUNDING: Janssen Oncology.
引用
- Voorhees PM, Sborov DW, Laubach J, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023. PMID: 37708911. doi:10.1016/S2352-3026(23)00217-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。